Attention around Oscar Health (OSCR) is building ahead of its forthcoming earnings release, where projections point to a significantly higher EPS than a year ago, set alongside expanding margins and rising operational efficiency.

Despite the upcoming earnings focus, recent trading has been weak, with a 30 day share price return showing a decline of 13.98% and a year to date share price return showing a decline of 25.58%, while the 3 year total shareholder return of 70.34% suggests the longer term picture has been much stronger.

If this kind of earnings driven story interests you, it can be worth widening your search with a curated list of 34 healthcare AI stocks

With Oscar Health shares down sharply in recent months despite higher EPS projections and improving margins, the key question is whether current weakness leaves the stock undervalued or whether the market is already pricing in future growth potential.

Most Popular Narrative: 29.4% Undervalued

Oscar Health's most followed valuation narrative pegs fair value at about $15.78 per share, well above the last close of $11.14. This puts a spotlight on what assumptions need to hold for that gap to close.

The analysts have a consensus price target of $11.143 for Oscar Health based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $14.0, and the most bearish reporting a price target of just $8.0.

Want to see why this narrative still points to upside even as targets and trading diverge? Earnings turning positive, margins shifting, and a richer future multiple all sit at the core of the model, along with a specific view on revenue growth and share count that could change how you see that $15.78 figure.

Result: Fair Value of $15.78 (UNDERVALUED)

However, there are still clear risks, including higher claims costs from changing ACA risk pools and policy shifts that could pressure membership growth and future margins.

Next Steps

With sentiment clearly mixed, both on recent price moves and future earnings, it makes sense to review the data yourself and decide where you stand. To see how the balance of concerns and potential upside currently looks, check out the 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If you stop with Oscar Health, you could miss other opportunities that fit your style, so take a few minutes to scan the wider market with focused stock lists.

• Target potential value opportunities by reviewing companies flagged as 61 high quality undervalued stocks that may offer more than the market currently reflects.
• Prioritise resilience by checking out 67 resilient stocks with low risk scores if you want businesses with lower risk scores at the core of your portfolio.
• Hunt for lesser known opportunities with the screener containing 26 high quality undiscovered gems and see which quality names the market may not be paying full attention to yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.